Emmanuel Dulac Net Worth

Emmanuel Dulac biography

Dr. Emmanuel Dulac Ph.D., Pharm.D. serves as Independent Director of the Company. Dr. Dulac has served as Chief Commercial Officer and Chief International Strategy at Alnylam Pharmaceuticals (Nasdaq: ALNY) since August 2016. Prior to Alnylam, Dr. Dulac was Senior Vice President, Global Head Rare Disease Business Unit, General Manager of United States Operations at Shire, plc (acquired by Takeda Pharmaceutical Company (NYSE:TAK)) from June 2014 to August 2016. Dr. Dulac held several leadership roles of increasing responsibility at Novartis (NYSE:NVS) from February 2006 to May 2014, including Vice President, Global Head Lung/Cystic Fibrosis. From August 2003 to February 2006, he served as Business Unit Lead for Cardiovascular Medicine at Abbott (NYSE:ABT). Dr. Dulac held several roles of increasing responsibility at Sanofi (Nasdaq:SNY) from October 1994 to August 2003, including Associate Director. Dr. Dulac earned a Doctorate in Pharmacology (PharmD, Ph.D.) from the University of Paris XI and IV and an M.B.A. from the ESSEC Business School in Paris.

How old is Emmanuel Dulac?

Emmanuel Dulac is 51, he's been the Independent Director of Proteostasis Therapeutics Inc since 2019. There are 7 older and 2 younger executives at Proteostasis Therapeutics Inc. The oldest executive at Proteostasis Therapeutics Inc is Franklin Berger, 70, who is the Independent Chairman of the Board.

What's Emmanuel Dulac's mailing address?

Emmanuel's mailing address filed with the SEC is C/O PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON, MA, 02135.

Insiders trading at Proteostasis Therapeutics Inc

Over the last 9 years, insiders at Proteostasis Therapeutics Inc have traded over $9,140,918 worth of Proteostasis Therapeutics Inc stock and bought 12,301,024 units worth $94,383,855 . The most active insiders traders include M James Barrett, Llc Fmr y Bioventures Ltd Novartis Ag.... On average, Proteostasis Therapeutics Inc executives and independent directors trade stock every 36 days with the average trade being worth of $3,463,082. The most recent stock trade was executed by Enterprise Associates 12, L... on 26 November 2019, trading 1,283,919 units of PTI stock currently worth $3,222,637.

What does Proteostasis Therapeutics Inc do?

Proteostasis Therapeutics Inc executives and stock owners

Proteostasis Therapeutics Inc executives and other stock owners filed with the SEC include:

• Meenu Chhabra,
  President, Chief Executive Officer, Director
• Marija Zecevic,
  Chief Operating Officer
• Benito Munoz,
  Chief Scientific Officer
• Jeffery Kelly,
  Independent Director
• Emmanuel Dulac,
  Independent Director
• Kimberlee Drapkin,
  Independent Director
• Badrul Chowdhury,
  Independent Director
• David Arkowitz,
  Independent Director
• Geoffrey Gilmartin,
  Chief Medical Officer
• Franklin Berger,
  Independent Chairman of the Board
• Eric Rabinowitz,
  Director
• Co Plc Perrigo Holdings Ltd...,
  
• M James Barrett,
  Director
• Asset Management, Lp Chen B...,
  
• James M. Detore,
  See Remarks
• Llc Fmr,
  
• Brett R Hagen,
  Principal Accounting Officer
• Po Shun Lee,
  See Remarks
• Bioventures Ltd Novartis Ag...,
  
• Enterprise Associates 12, L...,
  
• Eric D Larson,
  See Remarks
• Helen M Boudreau,
  Director
• Enterprise Associates 12, L...,
  
• Sheila Wilson,
  Chief Operating Officer
• Christopher T Phd Walsh,
  Director
• Janet L Smart,
  See Remarks
• Christopher Mirabelli,
  Director
• Romeo Mirzac,
  Principal Accounting Officer
• Christopher Health Care Ven...,
  
• Conor M Walshe,
  Director